Gene · 6431
Papers1,479
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,479
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CRNDE: A Pivotal Oncogenic Long Non-Coding RNA in Cancers. | Yale J Biol Med | 2023 | 38161583 | PubTator, text mining | PubMed |
| VIPpred: a novel model for predicting variant impact on phosphorylation events driving carcinogenesis. | Brief Bioinform | 2023 | 38156562 | PubTator, text mining | PubMed |
| Age-Related Alternative Splicing: Driver or Passenger in the Aging Process? | Cells | 2023 | 38132139 | PubTator, text mining | PubMed |
| Role of epithelial splicing regulatory protein 1 in cancer progression. | Cancer Cell Int | 2023 | 38110955 | PubTator, text mining | PubMed |
| RNA-binding proteins regulating the CD44 alternative splicing. | Front Mol Biosci | 2023 | 38106992 | PubTator, text mining | PubMed |
| Unveiling the role of miR-137-3p/miR-296-5p/SERPINA3 signaling in colorectal cancer progression: integrative analysis of gene expression profiles and in vitro studies. | BMC Med Genomics | 2023 | 38087342 | PubTator, text mining | PubMed |
| The Fundamental Role of Oxime and Oxime Ether Moieties in Improving the Physicochemical and Anticancer Properties of Structurally Diverse Scaffolds. | Int J Mol Sci | 2023 | 38069175 | PubTator, text mining | PubMed |
| Molecular characteristics and clinical implications of serine/arginine-rich splicing factors in human cancer. | Aging (Albany NY) | 2023 | 38015716 | PubTator, text mining | PubMed |
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. | Cancer Immunol Immunother | 2023 | 37973660 | PubTator, text mining | PubMed |
| Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2. | Cell Death Dis | 2023 | 37963919 | PubTator, text mining | PubMed |
| Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges. | Cancers (Basel) | 2023 | 37958473 | PubTator, text mining | PubMed |
| Alternative splicing induced by bacterial pore-forming toxins sharpens CIRBP-mediated cell response to Listeria infection. | Nucleic Acids Res | 2023 | 37941135 | PubTator, text mining | PubMed |
| Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma. | Epigenetics | 2023 | 37926963 | PubTator, text mining | PubMed |
| CAG repeat expansions create splicing acceptor sites and produce aberrant repeat-containing RNAs. | bioRxiv | 2023 | 37904984 | PubTator, text mining | PubMed |
| Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells. | Cell Commun Signal | 2023 | 37904233 | PubTator, text mining | PubMed |
| Role of RNA Alternative Splicing in T Cell Function and Disease. | Genes (Basel) | 2023 | 37895245 | PubTator, text mining | PubMed |
| L-Arginine Enhances Oral Keratinocyte Proliferation under High-Glucose Conditions via Upregulation of CYP1A1, SKP2, and SRSF5. | Molecules | 2023 | 37894498 | PubTator, text mining | PubMed |
| Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. | J Exp Clin Cancer Res | 2023 | 37880792 | PubTator, text mining | PubMed |
| Construction of predictive ceRNA network and identification of the patterns of immune cells infiltrated in Graves' ophthalmopathy. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2023 | 37875358 | PubTator, text mining | PubMed |
| Crosstalk between m6A modification and alternative splicing during cancer progression. | Clin Transl Med | 2023 | 37850412 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6431/papers?page=4